
OpGen OPGN
Quarterly report 2025-Q3
added 11-19-2025
OpGen Book Value 2011-2026 | OPGN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.38 M | -11.6 M | 7.58 M | 41.2 M | 21.2 M | 4.29 M | 3.31 M | 1.4 M | 3.17 M | 7.49 M | -8.07 M | -1.83 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.2 M | -11.6 M | 6.3 M |
Quarterly Book Value OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 M | 10.7 M | 7.05 M | 7.38 M | 2.99 M | -11.7 M | - | -11.6 M | 2.68 M | 6.86 M | 9.18 M | 7.58 M | 13.9 M | 27.4 M | 34.2 M | 41.2 M | 33.3 M | 39.7 M | 46 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 4.29 M | 4.29 M | 4.29 M | 4.29 M | 3.31 M | 3.31 M | 3.31 M | 3.31 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 3.17 M | 3.17 M | 3.17 M | 3.17 M | 7.49 M | 7.49 M | 7.49 M | 7.49 M | -3.5 M | -3.5 M | -3.5 M | -3.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 46 M | -11.7 M | 9.27 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
75.7 M | $ 13.65 | -0.44 % | $ 99.4 M | ||
|
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
228 M | $ 8.87 | 2.9 % | $ 591 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 151.97 | -2.34 % | $ 7.53 B | ||
|
Castle Biosciences
CSTL
|
456 M | $ 25.83 | 1.06 % | $ 717 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 17.32 | 1.82 % | $ 923 M | ||
|
DexCom
DXCM
|
2.75 B | $ 66.34 | 3.27 % | $ 25.9 B | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | $ 103.85 | 0.27 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 14.95 | 1.22 % | $ 452 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
20.9 M | $ 17.29 | -3.3 % | $ 2.24 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 87.18 | 1.98 % | $ 10.9 B | ||
|
Anixa Biosciences
ANIX
|
14 M | $ 2.84 | 0.35 % | $ 92.2 K | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 191.39 | 2.17 % | $ 136 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 97.61 | -0.73 % | $ 8.05 B | ||
|
IQVIA Holdings
IQV
|
6.63 B | $ 164.89 | 0.1 % | $ 28.3 B | ||
|
Illumina
ILMN
|
6.3 B | $ 119.28 | 0.29 % | $ 19 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.94 | -0.38 % | $ 22.1 B | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
5.39 B | $ 111.83 | 0.28 % | $ 34 B | ||
|
BioNano Genomics
BNGO
|
35.4 M | $ 1.11 | - | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 8.42 | -6.44 % | $ 239 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 78.5 | -1.25 % | $ 5.3 B | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
86 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 453.64 | 0.72 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 198.71 | 2.13 % | $ 24.7 B | ||
|
Celcuity
CELC
|
116 M | $ 114.9 | 0.6 % | $ 4.53 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.11 | 0.22 % | $ 1.98 B | ||
|
National Research Corporation
NRC
|
14 M | $ 17.4 | 5.33 % | $ 389 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.24 | 4.57 % | $ 1.06 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
706 M | $ 197.68 | 5.23 % | $ 19.5 B | ||
|
OPKO Health
OPK
|
1.37 B | $ 1.19 | - | $ 826 M | ||
|
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.36 | 2.26 % | $ 408 M |